Novartis has agreed to acquire Tourmaline Bio Inc., a clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease, for approximately $1.4 billion on a fully diluted basis. Pacibekitug complements Novartis’ cardiovascular strategy by targeting IL-6, a key upstream cytokine that promotes systemic inflammation, thus addressing a critical unmet need. With Phase 2 trials already well advanced, Novart...